Back to top
more

Denali Therapeutics (DNLI)

(Delayed Data from NSDQ)

$14.29 USD

14.29
2,013,687

-0.15 (-1.04%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $14.28 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in Denali Therapeutics Inc. (DNLI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.33% and 9.21%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Orchard Therapeutics PLC Sponsored ADR (ORTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues

by Zacks Equity Research

Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 251.16% and 2,502.86%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Denali (DNLI) Provides Update on Hunter Syndrome Study

by Zacks Equity Research

Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome).

Zacks Equity Research

Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.

Zacks Equity Research

Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122

by Zacks Equity Research

Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's

Zacks Equity Research

Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.68% and 15.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 3.85% and 28.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Heska (HSKA) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Heska (HSKA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Denali Therapeutics Inc. (DNLI) Q4 Earnings Expected to Decline

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 6.43% and 2.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus

by Zacks Equity Research

Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.